Galectin Therapeutic (GALT) Stock Price, Quote & News

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology

Sector: Healthcare

Phone: 678 620 3186

Website: galectintherapeutics.com

Address:

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

th3_fail_k1ng Sep. 10 at 1:57 AM

$GALT if this thing does run early and pre-squeezes before the buyout. We've got to hold the line for 24 hours let it squeeze a little bit hard The reason I say this is because of call options call options much like a shorts in margin calls buy at any price. But they don't execute until the following morning if you exercise early which is what people will have to do so we've got to hold the line for the call option holders because that'll jump the price up even more the following day and this should be a multi-day squeeze if everybody keeps their s*** together we work together then yeah we could launch it hard but we've got to keep our wits about us and remember that it's taken a long time to get here and if it ends up going early we've got to make the most of it .

1 · Reply

ThomasLD Sep. 10 at 1:53 AM

$GALT $10+ is going to be here in September!

0 · Reply

SamGantVHee Sep. 10 at 1:15 AM

$GALT based on the trend, ~$7.30 in sight imo The way it has been trading yesterday/today, really seems like it is itching to run...small gap ups during both days. Pull up the 1 min chart for this week and look at it yourself, very intriguing.

1 · Reply

johnhankowitz Sep. 10 at 1:06 AM

$GALT Just my opinion, but accumulate what you can here…this company will FINALLY fix the unmet need/space & is going to change lives in many positive ways 🤑😉

0 · Reply

Indibviduate1 Sep. 10 at 12:59 AM

$GALT

0 · Reply

jpfolsom Sep. 10 at 12:38 AM

$GALT

0 · Reply

BIGT80 Sep. 10 at 12:28 AM

$GALT the squeeze here could easily run 3,000 to 5,000% in a day. We just had 2 stocks in the last 2 days have those kind of runs. $100+ seems almost certain at this point!

0 · Reply

TheBigMaccccc Sep. 10 at 12:26 AM

$GALT tonight’s lucky number is …

0 · Reply

MoneyInc Sep. 9 at 11:59 PM

$GALT gap up and run tomorrow. We could see $6 quickly! I would not want to be short on this stock…

0 · Reply

Kenny83 Sep. 9 at 11:51 PM

$GALT

0 · Reply

Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

May 12, 2025, 8:00 AM EDT - 4 months ago

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Jan 10, 2025, 8:00 AM EST - 8 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Dec 20, 2024, 10:29 AM EST - 9 months ago

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Dec 20, 2024, 8:00 AM EST - 9 months ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Nov 18, 2024, 8:00 AM EST - 10 months ago

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Nov 14, 2024, 8:00 AM EST - 10 months ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

Oct 15, 2024, 8:00 AM EDT - 11 months ago

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

May 15, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

Mar 29, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

Mar 20, 2024, 8:11 PM EDT - 1 year ago

Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

Dec 7, 2023, 6:00 AM EST - 1 year ago

PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023

Nov 13, 2023, 8:45 AM EST - 1 year ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 13, 2023, 8:00 AM EST - 1 year ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

Nov 3, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

Oct 12, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GLTO

Sep 13, 2023, 5:22 PM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023

Sep 7, 2023, 12:00 PM EDT - 2 years ago

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update

May 15, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update

Apr 27, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases

Mar 30, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update

Mar 16, 2023, 8:00 AM EDT - 2 years ago

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Jan 24, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Jan 5, 2023, 8:00 AM EST - 2 years ago

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Nov 28, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Nov 14, 2022, 8:00 AM EST - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Nov 1, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences

Oct 12, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Sep 8, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022

Aug 15, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update

Jul 26, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

May 23, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress

May 16, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

Apr 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Mar 31, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update

th3_fail_k1ng Sep. 10 at 1:57 AM

1 · Reply

ThomasLD Sep. 10 at 1:53 AM

$GALT $10+ is going to be here in September!

0 · Reply

SamGantVHee Sep. 10 at 1:15 AM

1 · Reply

johnhankowitz Sep. 10 at 1:06 AM

$GALT Just my opinion, but accumulate what you can here…this company will FINALLY fix the unmet need/space & is going to change lives in many positive ways 🤑😉

0 · Reply

Indibviduate1 Sep. 10 at 12:59 AM

$GALT

0 · Reply

jpfolsom Sep. 10 at 12:38 AM

$GALT

0 · Reply

BIGT80 Sep. 10 at 12:28 AM

$GALT the squeeze here could easily run 3,000 to 5,000% in a day. We just had 2 stocks in the last 2 days have those kind of runs. $100+ seems almost certain at this point!

0 · Reply

TheBigMaccccc Sep. 10 at 12:26 AM

$GALT tonight’s lucky number is …

0 · Reply

MoneyInc Sep. 9 at 11:59 PM

$GALT gap up and run tomorrow. We could see $6 quickly! I would not want to be short on this stock…

0 · Reply

Kenny83 Sep. 9 at 11:51 PM

$GALT

0 · Reply

Bear_Police Sep. 9 at 11:44 PM

$GALT Sharing again! It works🙏🫡

1 · Reply

Manonfire8 Sep. 9 at 10:43 PM

$GALT shorts seem to have lost their will to fight? First time i've seen all green moves in AH.

1 · Reply

ThomasLD Sep. 9 at 9:27 PM

$GALT Excellent prediction! See you in the moon 🌕 in the near future!

1 · Reply

2TrustHim Sep. 9 at 9:23 PM

$GALT Alert On $BTBT!!! Moving After Hours!!!

0 · Reply

2TrustHim Sep. 9 at 9:19 PM

$GALT Rhyming Is Fun!!! GALT May VAULT 2 Months Away Don't STRAY

1 · Reply

AJB1891 Sep. 9 at 9:10 PM

$GALT very cool to see $5 and it’s pretty awesome to be involved in this right now. I picked up some $5 9/19 calls week and they’re starting to itch

0 · Reply

Bear_Police Sep. 9 at 8:56 PM

$GALT $300

0 · Reply

Belapectin Sep. 9 at 8:42 PM

$GALT great to see $5. I was in PT when it happened. Go Galt

0 · Reply

Gamaret Sep. 9 at 8:09 PM

$GALT When stocks break through the $5 barrier in a bearish manner and institutions sell, the market is flooded with shares and the price is pushed down. When a stock crosses this $5 threshold, institutions and hedge funds can, and sometimes do, load up on shares, driving the price up.

2 · Reply

Gamaret Sep. 9 at 8:07 PM

$GALT $5 - yes https://finance.yahoo.com/news/5-threshold-trading-strategy-explained-180144123.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAFoIUWWlvJFaEKo67ke55evBMEmBRi7ChDZjjwrQ0NCVcBRGmoH-7dlhDrw8HjnqZN6MDtHrFJ_8RGaFxZZXppCgOKM2vr0xKdiQXIqA9tyZNOqSayoN6BdrK_Uv8uOJdGQsYeqcDaKBBF8p6hdXptmw0hvpmatDUhbZrsnVgpVN

0 · Reply

TheBigMaccccc Sep. 9 at 8:03 PM

$GALT 309k traded volume…that’s pretty fking low

2 · Reply

Manonfire8 Sep. 9 at 7:57 PM

$GALT shorts right now

0 · Reply

Market Cap	299.16M
Revenue (ttm)	0.00
Net Income (ttm)	-47.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	312,800
Avg Vol	287,994
Day's Range	N/A - N/A
Shares Out	64.06M
Stochastic %K	87%
Beta	0.86
Analysts	Sell
Price Target	$6.00